The new unlock_ cohort has started

May 12, 2026

As of April, the new unlock_ cohort has begun. Ten Live Sciences & Health startups will work over the next year through training and coaching to strengthen their business idea through unlock_

Wondering which startups are participating in the program?

Meet the cohort

AromAb
AromAb is developing a new technology to purify antibodies for biological drugs more quickly and cheaply. Their method replaces the expensive standard technique (Protein A chromatography) with a more efficient chemical process that is more scalable and less costly for pharmaceutical production.
BlueTile Therapeutics B.V.
BlueTile Therapeutics is developing new drugs against severe and resistant fungal infections. Their technology focuses on safer and more effective antifungal treatments that can also work against fungi resistant to existing drugs.
Aziflu

Aziflu is developing new antiviral drugs against influenza (flu). Their focus is on treatments that work better than current agents, are less susceptible to resistance and can remain effective later in the infection.

CaraOmics

CaraOmics is developing a platform for building “clinical digital twins”: digital models of patients that predict how a disease develops or how a person responds to treatment. The platform helps hospitals and researchers turn existing patient data into actionable AI models faster and cheaper, without building complex data infrastructure each time.

Omivera

Omivera is developing a platform called CellEKT that allows pharmaceutical researchers to better measure how drugs behave in living cells. They are focusing on kinase inhibitors, an important class of drugs for cancer treatment, among other things.

Gateway Bio
Gateway Bio is a biotech startup that aims to address antibiotic resistance with a new type of drug delivery system. They are developing a modular nanocarrier platform that delivers antibiotics directly into bacterial cells, bypassing bacterial defense mechanisms. The platform is widely applicable to different types of antibiotics and works against both gram-positive and gram-negative bacteria.
QDiaMon
QDiaMon is a healthtech startup developing a wearable device that can measure multiple biomarkers from saliva within minutes. This gives sports teams real-time insight into performance, recovery and injury risk without a lab. The technology has already been technically validated and is intended for use in elite sports environments.
HeartSmart
HeartSmart is a biotech startup developing a human heart tissue model to improve heart failure drug development. Their Engineered Heart Tissue platform uses stem cells and a synthetic matrix to realistically measure heart contraction to generate better, more predictive preclinical data than traditional testing methods.
Radigene
Radigene is a biotech startup developing technology to track T-cell therapies in cancer patients throughout the body. This allows them to see where the therapy is during treatment and how effective and safe it is, which helps prevent failure in late stages of development.
ONEIRA
Oneira is a biotech startup working to improve cancer treatments by being able to better direct therapy response, including in resistant tumors. Their platform makes it possible to influence the effectiveness of existing drugs without changing the drug, dose or treatment duration.
To news overview

Meld je aan voor de nieuwsbrief!

Op de hoogte blijven van de laatste ontwikkelingen van alle innovators en ondernemers binnen de PLNT Community? Check het laatste nieuws.

Meld je aan!

Back to top